



Mission: The Coalition to Stop Flu is a multi-sector advocacy coalition dedicated to ending deaths from seasonal and pandemic influenza.


The Coalition's federal policy agenda is aimed at saving lives, saving money, and protecting public health by enhancing the U.S. influenza ecosystem, including ensuring adequate funding for priority influenza programs.

Coalition Members represent a unified advocacy voice for policy makers, including public health and patient advocacy organizations; academic, scientific, and research organizations; health care professional organizations; emerging biotech companies; pharmacy organizations; and vaccine, antiviral, and diagnostic manufacturers.

The Influenza Ecosystem


"As our country grapples with the worst public health crisis of our lifetimes, the consequences of years of underfunding our health care infrastructure and research and development are becoming clear. The infrastructure used for the Covid-19 response today is the same infrastructure that was built to address seasonal and pandemic flu. The federal government must dedicate sustainable annual funding to strengthening our public health sector and developing the vaccines, preventives, diagnostics, and treatments needed to end the threat of seasonal flu and protect us from the next pandemic."

—Former Senate Majority Leader Tom Daschle, Chairman, Coalition to Stop Flu



Coalition Members

Alvogen; American Heart Association; American Society for Microbiology; Association of Public Health Laboratories; Association of State and Territorial Health Officials; CVS Health; Families Fighting Flu; Genentech; GlaxoSmithKline; Immunization Action Coalition; Infectious Diseases Society of America; Inovio; National Association of City and County Health Officials; National Foundation for Infectious Diseases; Novavax; Sanofi; Seqirus; Trust for America's Health; Vir Biotechnology



Coalition funding priorities include increased federal funding for:

- The Centers for Disease Control and Prevention, to conduct flu surveillance, laboratory testing, and vaccination campaigns using the latest evidence-based messaging techniques;
- The Assistant Secretary for Preparedness and Response and Biomedical Advanced Research and Development Authority, to support the development and stockpiling of critical pandemic flu vaccines, preventives, antivirals, and diagnostics;
- The National Institute of Allergy and Infectious Diseases, to fund the long-term goal of developing “universal” flu vaccines, preventives, and new antiviral and diagnostics basic research; and
- Implementing the National Influenza Vaccine Modernization Strategy.

Coalition federal policy priorities focus on saving lives, saving money, and protecting public health through:

- Increasing influenza vaccination rates, including building vaccine confidence;
- Improving vaccine effectiveness, through improvements to current products and funding of innovative new options;
- Upgrading rapid detection and diagnostic capabilities;
- Developing treatment options and access to treatment;
- Modernizing public health data and surveillance infrastructure;
- Enhancing state and local response capabilities;
- Strengthening pandemic response, including stockpile management and distribution; and
- Expanding domestic manufacturing.

For more information about the Coalition to Stop Flu, please visit www.flucoalition.org or contact Niki Carelli, Executive Director, at niki@daschlegroup.com